Second line therapy in rheumatoid arthritis--a four year prospective study

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease.
• Second-line agents are crucial for managing RA.
• Long-term treatment adherence and efficacy are key concerns in RA management.

Purpose of the Study:

• To evaluate the long-term adherence and effectiveness of three second-line agents in rheumatoid arthritis patients.
• To assess patient outcomes after four years of treatment with sodium aurothiomalate, penicillamine, or levamisole.

Main Methods:

• A cohort of 123 rheumatoid arthritis patients initiated on sodium aurothiomalate (GST), penicillamine (P), or levamisole (L).
• Follow-up assessment at four years to determine treatment continuation rates and inflammatory indices.
• Comparative analysis of patient outcomes across the three treatment groups.

Main Results:

• After four years, treatment continuation rates were 39% for GST, 20% for penicillamine, and 8% for levamisole.
• Fifty-five percent of patients were on some form of second-line therapy at the four-year mark.
• Patients demonstrated improved inflammatory indices regardless of continued use of their initial second-line agent.

Conclusions:

• Long-term adherence varies significantly among different second-line agents for rheumatoid arthritis.
• Patient improvement in inflammatory markers was observed, but attribution to specific treatments versus disease natural history or healthcare engagement is uncertain.
• Further research is needed to elucidate the factors contributing to sustained improvement in RA patients on second-line therapies.